Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875960 · ClinicalTrials.gov registry record · Phase 4
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
A Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT06875960: Recruiting Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), sponsored by Bristol-Myers Squibb.
NCT06875960 is a Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants, below the 1,062-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06875960, a Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Conditions Studied
Interventions
- DRUG BMS-986165
Study Locations (4)
Connecticut
- Local Institution - 0001 - Farmington
New York
- New York University School Of Medicine - New York
Oklahoma
- Oklahoma Medical Research Foundation - Oklahoma City
Tennessee
- Local Institution - 0003 - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
What NCT06875960 shows while recruiting
NCT06875960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,062-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which BMS-986165 is the first listed.
NCT06875960 reports a single indexed study location in Connecticut, New York, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06875960 about?
NCT06875960 is a clinical study titled "A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132". The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
What is the current status of trial NCT06875960?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2026-02-27. Estimated completion is 2026-12-01.
What conditions does trial NCT06875960 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE).
What interventions are being tested in trial NCT06875960?
The interventions under investigation include: BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT06875960?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875960 being conducted?
This trial has 4 study locations across Connecticut, New York, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06875960's enrollment target sits among peer trials
35 12th of 14 higher than 3 of 14 other Systemic Lupus Erythematosus (SLE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus (SLE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
COMPLETED · Phase 4
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
-
Research Accelerated by You Lupus Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI